Recently, Chairperson Li Jiahong and President Leng Chunsheng of Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") led a team to visit Tofflon Science and Technology Group Co., Ltd. ("Tofflon"). They held in-depth discussions with Chairperson Zheng Xiaodong, Senior Vice President Zhang Haibin, and other senior executives of Tofflon. During the meeting, Mr. Zhang Haibin provided a detailed introduction on Tofflon's current business development, product portfolio, and future plans. After thorough discussions, the two parties reached a consensus and formally signed a strategic cooperation agreement. Under the agreement, they will carry out deep collaboration across multiple areas, including product R&D, equipment innovation, process optimization, and business cooperation.

The two industry leaders will integrate their strengths and resources to advance technological progress and industrial development in diabetes treatment. Together, they will explore new opportunities in pharmaceutical manufacturing and inject new momentum into China's pharmaceutical industry.

Mr. Li Jiahong, Chairperson of Tonghua Dongbao, commented, "As a pioneer in China's diabetes treatment field, Tonghua Dongbao has always been guided by innovation and driven by patient needs. In recent years, we have consistently increased our R&D spending and achieved major breakthroughs in the R&D of novel drugs, including insulin analogs and GLP-1 receptor agonists. Going forward, the Company will continue to deepen its presence in the domestic market while accelerating its internationalization to provide high-quality, accessible, innovative treatment solutions for more people with diabetes."

Mr. Zheng Xiaodong, Chairperson of Tofflon, commented, "Tonghua Dongbao's technical strengths and contributions to diabetes treatment are truly admirable. Tofflon and Tonghua Dongbao have maintained a friendly partnership for many years. We look forward to even more collaborations and exchanges to enhance vitality across our companies and the industry, and to promote the high-quality development of China's pharmaceutical industry."

About Tofflon

Tofflon (Stock Code: 300171.SZ) was established in 1993 and listed on the Growth Enterprise Market (GEM) in 2011. Headquartered in Shanghai, Tofflon provides integrated solutions for global pharmaceutical companies, covering process services and consumables, core equipment, and engineering services. Upholding the core value of "fortune favors the diligent", Tofflon stays committed to its mission of "serving biopharmaceuticals with expertise", and its strategy of "systematization, internationalization, and digitalization & intelligentization".

Tofflon has four core divisions: the Bio-process Division, the Preparation Equipment Division, the Engineering Division, and the Food & Beverage Division. To date, Tofflon has 26 holding subsidiaries in China, including Tofflon Life Science and Tofflon Dehui, 13 overseas holding subsidiaries, eight manufacturing bases worldwide, and three global R&D centers in China, the United States, and Germany. Tofflon continues to strengthen the research on drug manufacturing and pharmaceutical machinery manufacturing, and strives to build a "next-generation pharmaceutical manufacturing platform" to provide professional solutions for customers engaged in R&D, pilot production, and commercial production, helping accelerate drug R&D and large-scale commercial production.